Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Embracing Digital Health
A thought leadership article by Vicki Anastasi, Matt McCarty and Marie McCarthy, published by the Journal of mHealth, on the skills and expertise needed to best use mHealth to transform clinical trials, thereby improving the efficacy of therapies in the real world and increasing pharma R&D productivity.
-
Converging Goals: How a Focus on the Patient Drives Stronger Healthcare Partnerships
The foundation of healthcare is shifting from a provider-based to a patient-centric, or value-based, model. With aging populations, better-informed patients, and emerging technologies, the responsibilities and roles of every stakeholder in this industry is changing. Gain further insights on this topic from ICON expert Vicki Anastasi (VP, Global Head, Medical Device and Diagnostics Research, Real World Evidence Late Phase Research) in this recent MPO Magazine article.
-
How ICON is Using Analytics & Wearables to Enhance Clinical Trials
Read Computer Weekly's recent ICON article to learn how our company is investing in emergent technology to boost the attractiveness of trials as a care option and attract more participants, while enhancing internal efficiency around drug and device development.
-
Patients is a Virtue
As patients are increasingly using digital and social media as part of their consumer behaviour, it becomes important for healthcare to also be digitally enabled. In order to truly understand the value of direct patient engagement and advocacy, pharma companies need to take the time to understand how to grow successful, mutually beneficial relationships.
-
Navigating the Labyrinth of Regulation and Taking Drug Safety Reporting to the Next Level with Automation
An article published by Pharma focus, authored by ICON experts Arinder Sihota, PhD and Beata Kolon, on the challenges of global clinical trials in an ever-changing regulatory environment and the advantages of applying innovative automation to safety reporting.
-
Next generation of clinical trials
In this edition of Pharma Times, ICON's Tom O’Leary contributes to the discussion on the next generation of clinical trials in particular participant engagement, expansive data and the use of digital technology for patients and pharma.
-
Special Report on Immunology & Autoimmunity: Turn of the coin
A Drug Discovery News (DDN) article featuring commentary from Marco Silleni, discussing the challenges of autoimmune disorders. Silleni mentions the potential for extended therapy often means that regulatory authorities are much more focused on chronic toxicities and the requirement of long-term safety data. In addition, chronic autoimmunity diseases often mean lengthy trials and clinical monitoring, therefore the qualifications and skills of assessors are paramount.
-
Immunotherapy Combination Trials Q&A
Q&A article published by Pharmaceutical Market Europe (PME) featuring Chris Learn and Martin Lachs, discussing how best to achieve success in an increasingly crowded and competitive immuno-oncology field, where the rapid evolution of trial design has occurred as a competitive necessity.
-
ICON Introduces New Drug Safety Reporting Solution
An Outsourcing Pharma article featuring commentary from Quintin Van Wyk on ICON’s new drug safety reporting platform. Launched at DIA Europe, the platform automates complex processes to ensure compliance in an ever-changing regulatory space.
-
Adopting a Strategy to Identify Highest Commercial Value Products
A thought leadership article written by Vicki Anastasi, published by the Journal of Medical Device Regulation (JMDR), exploring the challenges of transitioning to the new EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) and advising manufactures on how to prioritise their product portfolio to ensure a smooth transition.
